Johnson & Johnson raises U.S. investment to over $55B in next four years

Johnson & Johnson announced manufacturing, research and development, and technology investments of more than $55B in the United States over the next four years. This represents a 25% increase in investment compared to the previous four years and builds upon the company’s already elevated U.S. investment levels resulting from the passage of the 2017 Tax Cuts & Jobs Act. In addition to the facility in Wilson, North Carolina, the company’s increased investment in the U.S. over the next four years includes: Three new advanced manufacturing facilities and the expansion of several existing sites across the company’s Innovative Medicine and MedTech businesses that will create high-paying, high-technology jobs. The company will share further information on these sites once available. Significant investments in extensive R&D infrastructure aimed at developing lifesaving and life-changing treatments in areas such as oncology, neuroscience, immunology, cardiovascular disease, and robotic surgery. Increased technology investments to help make drug discovery and development faster, support workforce training and enhance our business operations. With its increased investment over the next four years, the company’s U.S. economic impact will build upon its already estimated more than $100B per year.